This trial has been completed.

Condition hiv infections
Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
End date May 2008
Trial identifier NCT00000930, HIVNET 019


The purpose of this study is to see how HIV reacts in the immune systems of patients who have recently been infected with HIV. This study also examines HIV's resistance to anti-HIV drugs in newly infected patients.

Certain populations are good candidates for participation in HIV vaccine trials. These groups include men who have sex with men, IV drug users, and women at risk of getting HIV through heterosexual contact. Learning how HIV behaves in these populations once they become infected can help with the planning of future HIV vaccine studies.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective
HIV-infected individuals enrolled in HIVNET D01
Individuals with newly acquired HIV infection

Primary Outcomes

Detection of changes in HIV phenotype and genotype
time frame: Throughout study
Clinical progression rates
time frame: Throughout study
Antiviral resistance
time frame: Throughout study

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria Patients must have: - HIV infection, as documented by enrollment in HIVNET D01.1 (Part A patients) or by standard HIV serological tests or demonstrated HIV infection on virologic assay (Part B patients). Part A only: - Previous enrollment in infected-participants cohort of HIVNET D01. Part B only: - Initial HIV-seronegativity on an HIVNET protocol (other than an HIV vaccine protocol) and testing positive for HIV at a subsequent clinic visit. - Confirmation of HIV infection and documentation of HIV negative antibody test within 8 months of first positive test. Exclusion Criteria Co-existing Condition: Patients with the following conditions are excluded: - An obvious psychological/psychiatric disorder that would invalidate the informed consent process or otherwise contraindicate participation in the study. Prior Medication: Excluded: - Participation in a HIVNET HIV vaccine trial.

Additional Information

Official title Infected Participants Protocol: Evaluation of Natural History of HIV Infection in Newly HIV-Infected Persons in HIVNET Target Populations
Description This study provides an opportunity to prospectively monitor markers of HIV infection and disease progression in cohorts suitable for HIV vaccine trials. The detection of changes in HIV phenotype and genotype, clinical progression rates, and antiretroviral resistance within study populations over time are important for planning future HIV vaccine trials. This study consists of two parts. Part A includes HIV-infected patients who enrolled in HIVNET D01.1 (infected-participants cohort of HIVNET D01) and whose HIV disease has been closely monitored and characterized. This study continues to monitor these patients with follow-up evaluations every 3 months for the first 18 months and then every 6 months thereafter. Part B includes newly HIV-infected patients. These patients are monitored with clinical and laboratory evaluations at 0, 1, 3, 6, 9, 12, and 18 months, and then every 6 months through Year 5.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID).